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Abstract
Introduction: Successful population-level antiretroviral therapy (ART) adherence will be necessary to realize both the clinical
and prevention benefits of antiretroviral scale-up and, ultimately, the end of AIDS. Although many people living with HIV are
adhering well, others struggle and most are likely to experience challenges in adherence that may threaten virologic
suppression at some point during lifelong therapy. Despite the importance of ART adherence, supportive interventions
have generally not been implemented at scale. The objective of this review is to summarize the recommendations of clinical,
research, and public health experts for scalable ART adherence interventions in resource-limited settings.
Methods: In July 2015, the Bill and Melinda Gates Foundation convened a meeting to discuss the most promising ART
adherence interventions for use at scale in resource-limited settings. This article summarizes that discussion with recent
updates. It is not a systematic review, but rather provides practical considerations for programme implementation based on
evidence from individual studies, systematic reviews, meta-analyses, and the World Health Organization Consolidated
Guidelines for HIV, which include evidence from randomized controlled trials in low- and middle-income countries.
Interventions are categorized broadly as education and counselling; information and communication technology-enhanced
solutions; healthcare delivery restructuring; and economic incentives and social protection interventions. Each category is
discussed, including descriptions of interventions, current evidence for effectiveness, and what appears promising for the
near future. Approaches to intervention implementation and impact assessment are then described.
Results and discussion: The evidence base is promising for currently available, effective, and scalable ART adherence interventions
for resource-limited settings. Numerous interventions build on existing health care infrastructure and leverage available resources.
Those most widely studied and implemented to date involve peer counselling, adherence clubs, and short message service (SMS).
Many additional interventions could have an important impact on ART adherence with further development, including standardized
counselling through multi-media technology, electronic dose monitoring, decentralized and differentiated models of care, and
livelihood interventions. Optimal targeting and tailoring of interventions will require improved adherence measurement.
Conclusions: The opportunity exists today to address and resolve many of the challenges to effective ART adherence, so that
they do not limit the potential of ART to help bring about the end of AIDS.
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Introduction
Antiretroviral therapy (ART) has transformed HIV infection
from a terminal disease into a manageable chronic illness
[1]. ART can also reduce viral load (i.e. HIV RNA levels) and
the risk of secondary transmission, thus defining a new HIV
prevention paradigm in which successful treatment scale up
could help realize an end to AIDS [2,3]. The vast majority of
the 35 million people living with HIV (PLWH) are in resource-
limited settings (RLS), of whom an estimated 17 million were
receiving ART in 2016 (up from 1.3 million people in 2006) [4].
Targets aim to increase the number on treatment to 20million
people by 2020 [4]. While this ART expansion represents one
of the greatest public health achievements of our time, much
remains to be done. Shifts in ART initiation guidelines,
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including “test and start” and Option B+, in which all HIV-
positive pregnant women start ART, highlight potential chal-
lenges for ART adherence and retention among ever-growing
numbers of PLWH [5,6].
The level of adherence required to achieve improved
immune function and viral suppression varies, depending
primarily on ART regimen and prior duration of viral sup-
pression [7]; however, consistent dosing without sustained
gaps is critical for realizing both the individual and public
health benefits of ART [8–10]. ART adherence therefore
plays a key role in achieving the second and third “90s”
of the UNAIDS 90-90-90 campaign to end the AIDS epi-
demic (i.e. 90% on treatment and 90% virally suppressed)
[11]. As used here, “adherence” encompasses (1) medica-
tion initiation, defined as taking the first dose – not simply
receipt of a prescription; (2) dose-taking execution (i.e.
taking doses as prescribed) throughout treatment; and (3)
treatment persistence, meaning continuing therapy without
prolonged gaps (e.g. typically several weeks or longer) that
signal a permanent or temporary termination of therapy
[12]. Dose-taking execution and persistence both require
retention in care to facilitate timely prescription refills.
As ART access expands globally, medication adherence
remains challenging. Factors associated with achieving and
maintaining high ART adherence can be grouped according
to the individual (e.g. knowledge, resources, mental
health); interpersonal/network relationships (e.g. social
support, stigma); the community (e.g. socio-cultural
norms); health system factors (e.g. service provision) and
structural issues (e.g. access to services) [13]. Levels of
medication adherence are difficult to assess given variabil-
ity across available measures (discussed below); however,
concern for incomplete adherence is high [14] and esti-
mates of non-adherence range widely from 2% to 70%
[15]. According to a 2010 systematic review, one-third of
adults taking ART in sub-Saharan Africa lose viral suppres-
sion at 2 years [16]. While some estimates of viral failure
are lower than one-third [17], others are higher for several
reasons. First, adherence measured through research stu-
dies may be higher than that found in routine care, and
most published studies only report on individuals actually
retained in care. Second, current World Health Organization
(WHO) guidelines promote ART initiation at high CD4
counts, when individuals may be asymptomatic [18] – stu-
dies focused on such patients indicate mixed results [5,19].
Additionally, the impact of new regimens (e.g. integrase
inhibitors) and formulations in development (e.g. injectable
long-acting ART) on adherence is still unknown. Even with
favorable circumstances, however, most PLWH are likely to
experience challenges in adherence that threaten virologic
suppression at some point during lifelong therapy.
This article discusses ART adherence interventions, specifi-
cally defined as strategies to improve adherence and/or rele-
vant disease markers (i.e. HIV RNA, CD4 counts), and their
potential for adaption and adoption across RLS. Interventions
are considered broadly; however, some populations facing
unique challenges (e.g. youth, pregnant/post-partum women)
are highlighted. Because the global scale up of ART to meet
WHO targets of near universal coverage [18] will stress existing
healthcare delivery systems, effective interventions are pre-
sented in the context of scalability, which is defined as (1)
acceptance by PLWH and providers, (2) consistency with the
supply chain of necessary resources, and (3) affordability from
the perspective of the healthcare system providing ART.
Methods
In July 2015, the Bill and Melinda Gates Foundation convened
a meeting of clinical, research, and public health experts to
discuss promising ART adherence interventions for use at
scale in RLS. Specifically, experts were asked for interventions
that could be implemented for thousands of patients or more.
This article summarizes that discussion, with recent updates.
Meeting participants included experts with experience with
diverse types of ART interventions – targeting individual,
social, community, health system, and other structural factors
– as well as with multiple settings and key populations
affected by HIV (e.g. youth, pregnant/post-partum women,
substance users, men who have sex with men, sex workers).
The goal of this article is not to present a systematic review,
but rather to summarize considerations for programme imple-
mentation based on evidence from individual studies, sys-
tematic reviews, meta-analyses, and the WHO Consolidated
Guidelines for HIV, including evidence from randomized con-
trolled trials (RCTs), in RLS.
Results
Overview
Table 1 summarizes and provides examples of the interven-
tions discussed at the meeting. These interventions can be
categorized broadly as education and counselling; information
and communication technology (ICT)-enhanced solutions;
healthcare delivery restructuring; and economic incentives
and social protection interventions. Some interventions cut
across multiple categories, reflecting combination approaches;
these are organized by their dominant characteristic. Each
category is discussed below, including descriptions of interven-
tions, current evidence for effectiveness, and what appears
promising for the near future. Approaches to intervention
implementation and impact assessment are then described.
Categories of adherence interventions
Education and counselling
Overview
Education and counselling refer to communication strategies
that may target ART initiation, dose-taking execution, and/or
persistence. Education is an exchange of information about
medication to increase health literacy and reduce dosing
errors. Although the efficacy of education-only strategies is
unclear [50,51], patient-centered education (e.g. tailoring
information to address concerns, use of relevant metaphors)
is essential for standard medical treatment [52,53].
Counselling focuses on ART adherence-related beliefs,
attitudes, feelings, and skills in a collaborative patient-coun-
selor exchange. It involves (a) assessing needs and context,
(b) information about behavior change, (c) facilitating
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adherence behavior change to the extent that the patient is
able, willing and motivated, (d) identifying and modifying
goals, and (e) arranging for ongoing assistance or changes
in medication plans [54].
While adherence counselling is commonly included as a
core component of ART delivery, provision of high-quality
counselling is challenging when the number of patients
overwhelms providers, as is common in high burden RLS.
Moreover, counselling is influenced by the counsellor’s
training and is difficult to standardize (e.g. style of delivery,
tailored content). An immediate opportunity exists to
improve medication adherence by augmenting, supporting,
monitoring, and optimizing adherence counselling.
Promising and effective counselling approaches
Individual counselling delivered by trained interventionist(s).
A common model underlying individual counselling
interventions is cognitive behavioral therapy (CBT) [55].
CBT uses a collaborative process in which a provider acts
as coach and educator in helping patients identify thoughts,
feelings, and behavior cycles that influence adherence
[56,57]. Although more common in upper- and middle-
income countries, the use of CBT to promote ART adherence
is growing in RLS with promising impact on adherence
[20,22,58,59]. While expertise to train and supervise CBT
counsellors is limited, software and computer-assisted
approaches may expand capacity (discussed below).
Motivational interviewing (MI) is another approach that
has been used across diseases [60] and settings [61–63]. MI
is a patient-centered counselling style for eliciting behavior
change by helping patients explore and resolve potential
discrepancies between intentions and actual actions, as
well as increase motivation to change behaviors that are
inconsistent with those intentions; it is focused and goal
Table 1. Examples of ART adherence interventions with an impact on adherence and/or relevant disease markers for resource-
limited settings as discussed at the meeting and in the article*.
Categories of intervention
Interventions
Reference
citations
Education and
counselling
ICT-enhanced
solutions
Healthcare
delivery
restructuring
Economic incentives and social
protection interventions
Cognitive behavioral therapy [20–22] X
Motivational interviewing [23] X
Treatment supporters/assigned
community health workers
[24,25] X X
Patient adherence clubs [26] X X
Peer supporter [21,27–29] X
Peer-delivered directly observed
therapy
[30] X
Multimedia-based adherence
counselling
[31] X X
SMS reminder messages [32–34] X
SMS reminder messages with
follow-up or counselling
[35,36] X X
EDM-informed counselling [37,38] X X
Real-time EDM with SMS reminders [38–40] X
Electronic pharmacy refill tracking
system
[41] X
Task shifting ART delivery [29,42] X
Family-level economic strengthening
and savings program
[43] X
Cash and non-cash financial
incentives
[44,45] X
Nutrition education and/or food
assistance
[46–48] X X
Agricultural and microfinance
intervention
[49] X X
*This article is not a systematic review; some evidence-based interventions may not be shown in this table.
SMS = short message service, EDM = electronic dosing monitor.
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directed, but not simply advice-giving. MI may be brief
(even a single session) or may be used in combination
with other models, like CBT [64–66]. It can be delivered
by workshop-trained clinicians and does not require highly-
trained therapists [62]; however, optimal implementation
requires ongoing support, which has been shown to be
feasible in South Africa [64,67]. Adoption can be facilitated
through publicly available and culturally adaptable training
manuals and supervision tools [68], and is consistent with
the skilled-helper model already used in some LMIC.
Evidence for the impact of MI on ART adherence, CD4
count, and/or viral suppression in developed settings is
largely positive [69–74], though not completely [75].
Fewer studies have been undertaken in RLS, but positive
effects on adherence were reported in Nigeria [23].
Peer-delivered and family-centered adherence counselling
strategies
The WHO promotes peer support strategies for ART adherence
among PLWH, particularly among key populations [18]. In RLS,
individual peer-to-peer counselling and peer group support are
among the most widely-implemented adherence strategies
[21,24,27–30,76–84]. Peer-to-peer support often includes
counselling, psychosocial support (e.g. against stigma), and
assistance with navigation of care, as well as community ART
delivery, directly-observed therapy, and defaulter tracking
(some of which are discussed below). Titles for such providers
vary and include community or peer health workers; treatment
partners, supporters, or buddies; expert patients; and, in pre-
vention of mother-to-child transmission (PMTCT) programmes,
Mentor Mothers. Improvements have been seen in adherence,
while effects on viral suppression have varied [21,24,27–30]
and one intervention had no impact on adherence [81].
Adherence clubs, which often include peer-to-peer counseling,
also tend to demonstrate high levels of acceptability and pro-
mise for promoting adherence and viral suppression [26,85,86].
More evidence is needed for assessing the impact of standar-
dized peer counselling strategies on adherence in different
PLWH populations in RLS, such as among youth [76,82] and
pregnant/post-partum women [87,88]. Furthermore, potential
“turf-wars” with professional healthcare workers about the
scope of practice and competing roles [89] may need to be
minimized through clear definition of roles and integration of
peer counsellors into HIV programmes.
Family-centered counselling may be particularly important
for children and adolescents, as well as adults with concur-
rent challenges, such as mental illness [90,91]. One promis-
ing intervention delivered by lay staff has been developed in
South Africa [92]. Another family communication interven-
tion, originally developed to enhance coping with caregiver
depression, has been adapted to improve child mental
health and enhance family coping with HIV in Rwanda [93].
Looking to the future
Although not currently feasible in most RLS, optimized
delivery of high-quality adherence counselling with soft-
ware or other technology-enhanced strategies has recently
received increased attention [94]. Laptop or tablet-based
counselling tools can facilitate counsellor-patient
interactions, provide engaging and learning-based activities,
and offer visual graphics for concept demonstrations.
Preliminary data from one multimedia-based, lay counsel-
lor-delivered intervention in South Africa showed improved
pill count adherence [31,92].
Scalability of specific education and counselling stra-
tegies vary considerably based on current standard of
care conditions. In many regions, cadres of para-profes-
sionals, peers, and community support systems may be
readily identifiable or already engaged in delivery of HIV
care. Counsellors and nurse-counsellors are increasingly
common in care settings that serve large patient groups.
As such, the education and counselling interventions
identified often leverage existing resources. Optimizing
delivery of these strategies by ensuring quality training
and supervision, however, may require shifting available
resources.
Ict-enhanced solutions
Overview
ICT-enhanced solutions to support ART adherence include
cellular phones for direct communication with individuals
taking ART (e.g. automated short message services [SMS]
and voice calls); electronic dosing monitors (EDM), which
record the date and time of each monitor opening as a
proxy for medication ingestion; and electronic pharmacy
refill tracking systems – all of which potentially enable
intervention delivery. EDM data can be retrieved periodi-
cally from some devices through a cabled connection to a
computer or tablet, or in real time in other devices through
a cellular connection. Given the wide availability of cellular
networks globally and user-friendliness of many ICT-
enhanced solutions, such approaches are promising as
adherence-promoting strategies [95,96] and have potential
to improve all stages of adherence. For example, ART initia-
tion may be promoted through SMS for linkage to care and
monitored through EDM or pharmacy refill tracking sys-
tems, while SMS reminders/communication with or without
monitoring can support dose-taking execution and persis-
tence over time [12]. Challenges to deployment include the
need to keep cellular phones and/or EDM charged, gaps in
reliable network coverage, and low education and literacy
levels [97]. These challenges have been partially mitigated
by community charging stations, phone sharing, and
expanding cellular network availability. Misclassification of
dose-taking behavior may occur (e.g. taking multiple pills
out of an EDM for later dosing, device non-use, or inaccu-
rately reported adherence via SMS). However, the detailed
dosing histories obtained through EDM generally allow for
objective, precise, and accurate identification of incomplete
adherence [98,99].
Evidence for SMS
SMS communication to patients in RLS has demonstrated
promise in improving dose-taking execution [100–102],
although the evidence is mixed. In Kenya, an intervention
that used SMS to connect providers with PLWH and
assess self-reported adherence and health concerns
showed increases in self-reported adherence and viral
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suppression [35]. Another study of SMS reminders in
Kenya showed improvement in adherence as assessed
by EDM (used as a measurement tool) when the SMS
reminders were sent weekly, but found no impact with
daily reminders [33]. In Guatemala, daily SMS reminders
improved viral suppression [32] and in Nigeria twice-
weekly SMS reminders increased self-reported adherence
[36]. However, other well-conducted studies in Cameroon
and India showed no adherence or virological benefit
from scheduled reminders [103,104].
Evidence for EDM combined with counselling and/or SMS
Patients’ awareness of their adherence patterns can change
their dosing behavior. A review and meta-analysis of adher-
ence enhancing interventions in 79 RCTs, in which electroni-
cally compiled drug-dosing histories were assessed, showed
that feedback to patients about their dosing patterns was the
largest factor influencing adherence [105]. Several studies
have confirmed that using EDM data to inform counselling
improves ART adherence and CD4 cell counts [37,38,106].
Recent studies using real-time EDM to deliver SMS trig-
gered by late dose-taking, however, have shown generally
positive results. One study in China combined triggered
reminders with data-informed counselling and found an
increase in EDM adherence [38]. A similarly designed
study of EDM-triggered SMS reminders in South Africa
(that did not include supportive counselling) observed a
decrease in treatment interruptions of >72 h, but no effect
on overall adherence [40]. A pilot RCT in Uganda that
tested both scheduled reminders and triggered reminders
combined with real-time EDM found improved adherence
and a decrease in treatment interruptions only with sched-
uled reminders [39]. None of these EDM studies was pow-
ered to assess viral suppression. Additionally, a recent four-
arm study using a mix of EDM and SMS for individuals
receiving tuberculosis treatment in China found a reduction
in incomplete adherence using a combined EDM-SMS
approach, but no effect from SMS alone [107].
Understanding the mixed evidence
The variation in these studies may stem from the timing and/or
content of SMS messages, existing adherence barriers in each
population, and other individual or cultural preferences for the
SMS or monitoring [108]. In a review of global SMS interven-
tions for adherence in conditions not restricted to HIV, two-way
communication (versus one-way messaging) was found to be
the main driver of SMS-based adherence improvements [109].
Further assessments are needed with both scheduled and
triggered SMS reminders/communication in different settings
and populations, alongwith testing of combination approaches.
Electronic pharmacy refill tracking systems
Another promising technology is use of electronic pharmacy
refill tracking systems. These systems have been used in
Haiti to differentiate ART failure risk and could be linked to
alerts for clinical follow-up [41]. They have also been shown
to accurately reflect retention in care in Malawi and South
Africa [110,111], thereby reducing staff time and effort.
Looking to the future
Currently, approaches that rely on cellular phones and
existing computer record systems are more affordable
than EDM-based platforms, and thus have greater potential
for immediate scale up. Both EDM and electronic pharmacy
refill tracking systems have the advantage of generating
real-time adherence information, and may identify patients
for targeted use of viral load testing and/or prompt inter-
vention prior to virologic failure. Over time, the ability to
focus resources on patients at high risk of virologic failure,
as well as the probable decline in technology cost, may
make these interventions cost-neutral or cost-saving [112].
Importantly, recent modelling found that EDM would be
cost-effective with or without the availability of viral load
testing at <US$50 [113]. Additionally, ICT-enhanced solu-
tions have generally been acceptable to PLWH [114], which
will facilitate scale up, although privacy (e.g. unintended
disclosure of HIV status resulting from EDM use) and other
concerns may be an issue in some settings or populations
[115,116]. Both EDM and SMS have generally been found
to create a sense of “connectedness” to clinics [117,118]
and to motivate patients who appreciate “being watched”.
These findings – and the increasing connectedness of peo-
ple through technological advances globally – suggest that
electronic interventions, whether harnessing existing
phones or putting devices in patient’s hands, have potential
for reaching and supporting large numbers of PLWH.
Healthcare delivery restructuring
Overview
The organization of people, institutions, and resources that
deliver healthcare, referred to broadly as healthcare deliv-
ery systems, can affect adherence [119–122]. For example,
long wait times at clinics, fragile supply chains leading to
stock outs, or extended travel to clinics can make it difficult
to obtain care and avoid treatment interruptions. Patient
interactions with healthcare workers can also influence
adherence [123–125]. In many RLS, healthcare delivery
systems remain poorly equipped to provide long-term
chronic disease care, including HIV care many are over-
burdened by high patient loads and limited resources
[126]. This burden has increased with rapid ART scale-up,
more inclusive ART eligibility, and plateaus in international
funding [127].
Improvements in structural, logistical, and interpersonal ele-
ments of healthcare delivery can improve the overall efficiency
of crowded service delivery centers. For example, decentralized
services decrease the demands on patients for care seeking,
such as transportation and time away from work [128]. Other
techniques, such as point-of-care CD4 count testing [129] and
integration of related services (e.g. antenatal care and PMTCT
programmes; tuberculosis and HIV treatment programmes
[130,131]), improve linkage to and retention in care. Likewise,
emerging interventions such as differentiated models of care
(discussed below) are designed to improve efficacy of treat-
ment programs. While not necessarily targeting adherence,
these interventions enable better care delivery.
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Evidence for current adherence interventions
Several intervention studies and pilot programmes have
shown that streamlining and reducing the burden of clinic
visits and medication refills are well-received and specifically
effective at promoting adherence. Most involve community-
based or alternative care delivery models and task shifting to
nurses [29,42,121]. In some delivery models, PWLH with per-
ceived good adherence (e.g., those who maintain viral sup-
pression) can obtain ART via an adherence club [26,85,86].
These clubs enable a “fast-track” refill mechanism, as well as
provide adherence counselling and peer support, as men-
tioned above. They have been found to reduce losses to
follow-up and virologic rebound in already virologically sup-
pressed patients [26]. Adherence clubs, however, are unlikely
to increase poor adherence levels without concurrent coun-
selling. Similar fast-track, nurse-led care has been used suc-
cessfully to reduce loss to follow-up and death among high-
risk patients initiating ART with low CD4 counts [132]. Another
approach shown to reduce the care burden without compro-
mising care uses a group-based shared responsibilitymodel, in
which one group member collects symptom reports and
obtains ART refills for all group members [42]. In yet another
model, patient-defined support networks improved clinic
attendance [28].
Looking to the future
Patient-oriented adaptations of healthcare delivery systems
can overcome structural barriers, reduce transportation
costs and waiting times, and ultimately lessen treatment
fatigue and losses to follow-up. These adaptations can also
increase time and/or resources for disclosure, treatment
education and social support – all of which are beneficial
for ART retention and adherence. Moreover, they may
improve patient care if the efficiencies gained reduce the
burden on providers and improve the provision of addi-
tional or improved services. Implementation science
research that evaluates these adaptations at scale and
assesses cost-effectiveness is needed, as are partnerships
with local Ministries of Health and other stakeholders who
are key to systems-wide changes [133]. Changes in health-
care delivery often require resources from multiple aspects
of healthcare systems, thus limiting scalability. However,
once changes have been established and produce desired
outcomes, they can be self-sustaining by freeing otherwise
encumbered resources.
Economic incentives and social protection interventions
Overview
Economics, psychology, and social inclusion theories guide
the development and implementation of economic-based
interventions. A broad consensus is emerging to suggest the
need to differentiate between the impairments inflicted by
poverty [134] and the avenues to address poverty, which
include conditional and unconditional incentives (i.e. cash
transfers); food security and livelihood support; and social
protection programmes [135,136]. Social protection is gen-
erally understood as public actions to address poverty,
economic shocks, and social vulnerability [137]. Income or
in-kind support programmes directed at these concerns can
help increase access to services and thereby increase ART
adherence. Contingency management interventions use
incentives to motivate behavior change to counter indivi-
dual behavioral choice [138,139]. More broadly, conditional
cash transfers at the national level are designed to reduce
poverty, increase social protection, and improve education
outcomes [140], thereby improving HIV treatment
outcomes.
Unconditional and conditional economic incentives
Current incentive practices vary widely by type, amount,
length of duration, and conditionality. Compared to condi-
tional economic incentive programmes that use specific elig-
ibility criteria, unconditional economic incentives may have
lower administrative burden, thus favoring scalability, while
producing similar results, as seen in rural Kenya and with
adolescent girls in Malawi [141,142]. Non-cash transfers (e.g.
loans plus training, in-kind loans, forgivable grants plus train-
ing) can also be used as incentives. Some of these models (in
some cases including EDM) are being tested for impact on
adherence-related behaviors and other HIV-related out-
comes in RLS [43,143]. With any incentive program, it is
important to recognize that incentives can motivate patients
to misreport their circumstances to qualify for programmes.
The problem of misreporting can be mitigated by using
objective eligibility measures (e.g. biological testing) or
other indicators verified by a third party [141], or by making
the programmes universal (i.e. non-means tested) [144].
In the United States, five RCTs of conditional economic
incentives have demonstrated increased ART adherence
[145], though one community-based trial had mixed results
[146]. Less is known about the application of cash incen-
tives conditional on adherence in RLS. One RCT in India
among substance users showed increased linkage to care
and ART initiation, but no difference in viral suppression
[45]. Preliminary results from an RCT among adults in
Uganda, however, found improved adherence with small
prize incentives [44]. In a large RCT of unconditional cash
transfers versus a wait-list control in Uganda, cash transfers
had no effect on adherence, retention, or mortality,
although the study found a small, significant decrease in
CD4 cell rebound among transfer recipients [147].
Importantly, even if cash transfer programmes are effective
in RLS, sustainability and scalability without a steady influx
of resources from donors or governments is unclear, parti-
cularly where political will is lacking [136]. The use of small
incentives or lotteries may keep costs low and increase
potential for scalability.
Food security interventions
Food insecurity is a critical determinant of incomplete ART
adherence in RLS [148–152]. Some economic interventions
take the form of in-kind loans or grants, like food vouchers
and targeted food assistance, which have been recommended
for HIV treatment packages in RLS [153–155]. Studies in sub-
Saharan Africa, Haiti, and Honduras have found that food
supplementation delivered as part of HIV care can lead to
better ART adherence and improved clinic attendance [46–
48]. A study in Zambia showed that more participants in the
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food supplementation group achieved high adherence com-
pared to controls [47]. In a summary of the evidence on food
assistance and adherence to both HIV and TB therapy, eight of
ten studies found that food provision improved adherence to
ART or TB treatment completion [156].
Notably, while cash transfers and food supplementation
may be appropriate during early linkage to care and ART
initiation, they are limited in scalability and sustainability in
the absence of ongoing government or donor funding com-
mitments. Moreover, they do not address upstream deter-
minants of food insecurity [148–152].
Promising approaches to economic and livelihood
interventions
Livelihood interventions that include microloans and/or
business skills training are a promising strategy to help
families overcome economic barriers to sustained adher-
ence. Given the political and financial challenges of condi-
tional cash transfer interventions, agricultural interventions
and savings-led groups may have a better chance of sus-
tainably improving health outcomes at scale.
While data are limited, one recent study of an agricul-
tural and microfinance intervention in Kenya found signifi-
cantly improved viral suppression, CD4 counts, and food
security among PLWH [49]. In an ongoing longitudinal qua-
litative study, this intervention also improved ART adher-
ence and clinic attendance, and reduced HIV-related stigma
and discrimination [157]; its impacts on stigma were
hypothesized to occur through restoration of health,
increased social integration, and an increased ability to
make reciprocal economic contributions to community
safety nets [158]. The same study also found changed
gendered power dynamics, reduced high-risk behaviors,
and improved prioritization of health [157,159].
The specifics of which poverty-alleviation interventions are
scalable and most effective are being evaluated in clinical
trials (e.g. NCT01957917; NCT01790373) and may vary by
country and context. Identifying and addressing economic
barriers to health and evaluating the impact of different
incentive and livelihood-promoting strategies on medication
adherence are key research needs. Ultimately, interventions
implemented at the health systems level may make the most
difference at scale. For example, the national conditional cash
transfer programme in Mexico, Oportunidades, in operation
since 1998 and covering over 25 million people, is associated
with higher affiliation to Seguro Popular (the Universal Health
Insurance Program for the Poor) [160]. That programme, in
turn, has enabled Mexico to provide universal ART access
[161]. Similarly, national level ART investments since 1996
have provided population benefits in Brazil [162].
Targeted and tailored adherence support
Some adherence support may be useful for all individuals
taking ART; however, most interventions should be focused
on those who struggle with adherence, thus enabling more
directed and cost-effective implementation. Interventions
should also be combined and tailored when possible to
optimize close matching between the preferences and
capacities of PLWH, providers, and healthcare delivery sys-
tems. Treatment initiation, dose-taking execution, and
treatment persistence are different behavioral processes
and may best be served by different approaches. Many
individuals fail to persist with treatment relatively soon
after treatment initiation [163–165]. This phenomenon sug-
gests that initiation is a particularly vulnerable time during
which extra efforts to keep PLWH engaged with their care
are warranted. For example, assistance with integrating
medication taking into every-day life, learning to cope
with potential HIV-related stigma, and dealing with poten-
tial side effects may be sources of early non-persistence.
PLWH who remain on treatment, but with gaps, may have
different problems, such as difficulty finding transportation
to refill medications, a perception that improved health
renders regular medication taking unnecessary, or long-
term side effects, such as lipodystrophy. Individuals who
interrupt therapy may quit care altogether, necessitating
efforts to find and re-engage them. Moreover, needs and
preferences of healthcare systems and cultures may differ.
For instance, the strength of existing counselling pro-
grammes varies across institutions. Some groups may
respond better to messages delivered through commu-
nity-based theatre or music, while others prefer individual
counselling. Technology acceptance may be high in one
area and low in another. Understanding these varying pre-
ferences is critical for choosing adherence interventions.
Appropriately targeted and tailored adherence support
requires accurate measurement of adherence. While many
adherence measurement tools exist, none is perfect [166].
The strengths and limitations of each measure are listed in
Table 2. Importantly, “average” or “good” adherence (e.g.
80%) can be misleading, particularly when based on self-
report, pill counts, and other methods with potential for
strong positive bias. Adherence patterns (i.e. sustained
interruptions), including treatment discontinuation, are
generally more important than average adherence in deter-
mining risk for viral rebound [7,167]. Additionally, measures
obtained during clinical care do not reflect challenges for
those lost to follow-up, and thus likely represent
underestimates.
Implementation and evaluation of adherence
interventions
Figure 1 provides schematics of two general approaches to
consider in choosing adherence interventions for optimally
targeted and tailored support: the funnel and the menu.
With a funnel approach, all individuals receive basic ART
education and counselling and are screened for incomplete
adherence by one of the above-noted monitoring tools.
Those identified with incomplete adherence (which may
include those not initiating care) receive a standard inter-
vention. For those continuing to experience adherence
challenges, subsequent interventions of increasing intensity
may be needed. Of note, the first intervention should be
appealing to dissuade PLWH from missing medication to
gain benefits of later steps in the funnel (e.g. incentives).
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Table 2. Strengths, limitations, potential advances, and other considerations for adherence monitoring tools that may be used for targeted and tailored support.
Monitoring tool Strengths Limitations Potential advances/considerations
Subjective
Self-report ● Easy and relatively inexpensive to collect
● Reported missed doses are likely accurate [169]
● Correlates with viral suppression in some contexts
[170–173]
● Generally overestimates adherence due to social
desirability and recall bias [174,175]
● Difficult to assess patterns of adherence
● Collected too infrequently to reliably detect incom-
plete adherence, non-persistence, or risk of virologic
failure [176]
● SMS may decrease social desirability and recall
biases, as has been shown with other forms of tech-
nology [177,178]
Objective
Pill counts ● Easy and relatively inexpensive to collect
● Returned pills strongly suggest incomplete
adherence
● Tends to overestimate adherence due to social desir-
ability bias, i.e. “pill dumping” [179,180]
● Provides only an average adherence and cannot
assess patterns
● Unannounced pill counts are less subject to manipu-
lation, but are resource intensive [181]
Pharmacy refill ● Already collected by most clinics
● Reveals failures of ART initiation and persistence
● Correlates with clinical outcomes [182]
● Useful for population trends and specific poor
performing groups (e.g. a WHO “early warning
indicator”) [183]
● Provides maximal predicted average adherence and
may miss incomplete adherence
● Many existing pharmacy systems are not optimized
for tracking
● Could be made actionable for intervention deploy-
ment if made available to clinicians or community
health workers
Electronic dose
monitoring
● Only method to provide day-to-day patterns, which
better predict the risk of virologic failure compared
to the average adherence [7,167,184,185]
● Allows for tailored counselling and intervention
deployment, potentially in real time
● Currently expensive and resource-intensive
● Technical challenges (e.g. battery failures) and device
non-use (e.g. “pocket dosing”) may limit accuracy
● Additional development needed to improve technol-
ogy and reduce cost for use in clinical settings
● Could be used intermittently to reduce costs (e.g.
during ART initiation or only for intensive support)
Drug detection ● Only measure to directly assess drug ingestion (e.g.
plasma, hair, dried blood spots) [186,187]
● Currently expensive and resource-intensive
● Some methods reflect recent (e.g. plasma indicates ~3
half-lives) rather than typical dosing
● Provides only average adherence
● Inter- and intra-individual variability limit interpreta-
tion [188]
● Information generally not available until after the
patient encounter, making interventions challenging
● Additional research needed for use in clinical settings,
including point-of-care methods and regional labora-
tory capacity
Viral loada ● Indicates sufficient adherence for clinical benefits
for guiding targeted and tailored support [189]
● Currently expensive and resource intensive, especially
over a lifetime [190]
● Information generally not available until after the
patient encounter, making interventions challenging
● Incomplete adherence may not be detected until
after drug resistance has developed, leading to a need
for expensive, often unavailable second-line ART
● Lack of drug resistance testing limits interpretation
● Low-cost, point-of-care viral load monitoring would
increase access, allowing for complementary role
along with adherence monitoring and interventions
aViral load is not a direct measure of adherence. Rather, it indicates sufficient adherence to achieve viral suppression, which signals success in achieving the clinical benefits of ART.
Comments are drawn from the literature as cited, as well as overall reviews [8,166,168]
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With the menu approach, a number of options are offered,
allowing individuals to choose their intervention strategy.
Menus could be tailored for specific populations. Combined
approaches with basic and more intensive strategies avail-
able as a “menu of options” at each level of the funnel
might also be possible. Strategies are adapted to local
cultures and communities, addressing setting-specific chal-
lenges and leveraging local resources. A process of contin-
uous quality improvement is advisable to help optimize the
strategies for a given population or setting, such as a Plan-
Do-Study-Act cycle [191,192].
Several techniques will assist in the evaluation of adher-
ence intervention implementation. First, adaptive and
sequential research designs within implementation science
frameworks may be particularly efficient and informative;
such trials are ongoing (e.g. NCT01904994, NCT02338739).
Second, study designs typically focus on the short term (i.e.
one year or less) and miss important challenges, as well as
long-term positive effects; longer follow-up is critical for
understanding more comprehensive impact. Third, research
results often fail to translate into real-world changes
because they are typically conducted in relatively well-
resourced settings and with relatively high-functioning
patients; future studies need to be conducted in general-
izable settings [193]. Finally, all interventions should be
assessed with clearly defined adherence and adherence-
related outcomes (e.g. reduction of unmet needs, positive
attitudes and beliefs about care, cost-effectiveness) in addi-
tion to viral suppression.
Consideration of specific populations
ART adherence interventions have thus far been presented
with little reference to specific populations (which is
beyond the scope of this article). Adherence monitoring
and interventions may require adaptation for different
populations and research in these areas often lags that in
the general population. In particular, few evidence-based
interventions have been developed to promote adherence
in children and adolescents [76,194], for whom interven-
tions shown to be effective in adult populations may not be
helpful [195]. While increased adherence monitoring and
support may be disproportionately needed for key popula-
tions, not every member of a key population needs help.
Tremendous variation exists within vulnerable populations,
and among those believed to be at low risk, especially as
life circumstances change over time. Additionally, imple-
menting interventions at scale for some populations may
prove quite challenging, thus requiring more resources.
Discussion/conclusions
The evidence base is promising for currently available,
effective, and scalable ART adherence interventions for
RLS. Participants at the meeting identified numerous inter-
ventions that build on existing healthcare infrastructure and
leverage available resources. Those most widely studied
and implemented to date involve peer counselling, adher-
ence clubs, and SMS. Many additional interventions could
have an important impact on ART adherence with further
development, including standardized counselling through
multi-media technology, electronic dose or pharmacy mon-
itoring, decentralized and differentiated models of care,
and livelihood interventions. Although cost can pose a
barrier to implementing adherence interventions, the
value of supporting high adherence and associated viral
suppression warrants consideration of investment, particu-
larly as the technology to support these efforts becomes
Figure 1. Examples of funnel and menu approaches for targeted and tailored implementation of ART adherence interventions (other
interventions could be substituted). With a funnel approach, all individuals would receive basic education and counselling. Based on one
or more adherence measures (see Table 2), individuals identified with incomplete adherence would receive a standard intervention. The
intensity of intervention would then increase for the likely decreasing number of individuals who continue to have adherence challenges.
With the menu approach, a number of intervention options could be presented to individuals, allowing them to choose their intervention
strategy. Menus could be tailored for specific populations (e.g., individuals with depression may opt for counselling, those with structural
barriers may benefit from adherence clubs). A combined approach with basic and more intensive strategies offered as a menu at each
level of the funnel could be considered.
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more affordable. Scalability of these interventions will need
to be assessed outside of the research context and in
settings with limited additional resources [193]. Even
when immediate resources do not include critical interven-
tion ingredients (e.g. peers, adherence clubs), retooling,
shifting, and reallocation of resources can identify avenues
for sustainable new or improved intervention approaches.
When combined with differential care delivery strategies,
new resources can be potentially discovered.
A key area for development is more active and accurate
adherence monitoring to enable the targeting of adherence
support for those with the greatest need. Real-time EDM
and electronic pharmacy refill tracking systems are two ways
to achieve such precise monitoring [196]. Because only a
minority of patients miss sufficient doses of ART to threaten
viral failure, selective targeting of interventions based on
adherence assessments allows for greater investment in
more resource-intensive interventions for those patients
who truly need them, with the potential for differential,
patient-specific, and cost-saving interventions. Engagement
in care is critical, but engagement alone does not ensure the
adherence required for sustained viral suppression.
Moreover, adherence may change over time and is subject
to disruptions in routine (e.g. sentinel life events, like a death
in the family). Newer antiretroviral medications (e.g. inte-
grase inhibitors) may be available in RLS in the near future,
allowing more forgiveness for missed doses [197]; however,
feasible and acceptable monitoring and associated support
strategies will still be needed over a lifetime of treatment.
Implementation of adherence interventions at scale will
face important challenges. First, healthcare delivery sys-
tems, at both regional and national levels, will have to be
receptive and committed to widespread implementation.
Human and financial investment must be weighed carefully,
making cost-effectiveness and the overall impact of candi-
date interventions critical. Second, monitoring and evalua-
tion of ongoing adherence programmes, as well as research
into new interventions, will require funding beyond what is
typically invested in single intervention studies. One of the
goals of this article is to emphasize both the need for this
investment, as well as its potential benefits.
Given the availability of encouraging and robust evidence,
the opportunity exists today – more than ever before – to
address and resolve many of the challenges to effective ART
adherence, especially as access extends to increasing numbers
of PLWH. We now have an opportunity to draw on a wealth of
tested ART adherence technologies and interventions to
expand support to PLWH so that adherence challenges do not
limit the potential of ART to help bring about the end of AIDS.
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